ABT - CIK 0000001800
ABBOTT LABORATORIES (ABT) reported revenue of $41.95B for fiscal year 2024, up 4.6% from $40.11B in fiscal 2023. The figure comes from the company's audited annual report as filed with the SEC.
| Quarter | Period end | revenue |
|---|---|---|
| Q1 | 2024-03-31 | $9.96B |
| Q2 | 2024-06-30 | $10.38B |
| Q3 | 2024-09-30 | $10.63B |
Calendar quarters as standardized by SEC XBRL frames; the company's fiscal calendar may offset from calendar quarters.
ABBOTT LABORATORIES (ABT) reported revenue of $41.95B for fiscal year 2024, up 4.6% from $40.11B in fiscal 2023. The figure comes from the company's audited annual report as filed with the SEC.
In the following fiscal year (2025), ABBOTT LABORATORIES reported revenue of $44.33B, an increase from the $41.95B reported in fiscal 2024.
See the full ABT revenue history or the complete income statement.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.